BCS12

Overview

BCS12 is a CAIX inhibitor. BCS12 inhibits the viability of cancer cells under hypoxic conditions. BCS12 elevates ROS levels and suppresses the expression of HIF-1α and CA9 . BCS12 downregulates Bcl-2 , activates caspase-9 , caspase-3 , caspase-7 and Bax , and induces PARP cleavage and apoptosis . BCS12 reduces tumor burden, increases the number of apoptotic nuclei and restores tissue structure in rats bearing breast tumors. BCS12 can be used in research related to triple-negative breast cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > PARP | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Carbonic Anhydrase | Products > Signaling Pathways > HIF/HIF Prolyl-Hydroxylase

Product Information

• Catalog No.: HY-186248
• CAS No.: 329719-71-3
• Molecular Formula: C17H16ClNO2S
• Molecular Weight: 333.83
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source